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Abstract
To understand how miRNAs contribute to the molecular phenotype of adipose tissues and related traits, we performed
global miRNA expression profiling in subcutaneous abdominal and gluteal adipose tissue of 70 human subjects and
characterised which miRNAs were differentially expressed between these tissues. We found that 12% of the miRNAs were
significantly differentially expressed between abdominal and gluteal adipose tissue (FDR adjusted p,0.05) in the primary
study, of which 59 replicated in a follow-up study of 40 additional subjects. Further, 14 miRNAs were found to be associated
with metabolic syndrome case-control status in abdominal tissue and three of these replicated (primary study: FDR adjusted
p,0.05, replication: p,0.05 and directionally consistent effect). Genome-wide genotyping was performed in the 70 subjects
to enable miRNA expression quantitative trait loci (eQTL) analysis. Candidate miRNA eQTLs were followed-up in the
additional 40 subjects and six significant, independent cis-located miRNA eQTLs (primary study: p,0.001; replication:
p,0.05 and directionally consistent effect) were identified. Finally, global mRNA expression profiling was performed in both
tissues to enable association analysis between miRNA and target mRNA expression levels. We find 22% miRNAs in
abdominal and 9% miRNAs in gluteal adipose tissue with expression levels significantly associated with the expression of
corresponding target mRNAs (FDR adjusted p,0.05). Taken together, our results indicate a clear difference in the miRNA
molecular phenotypic profile of abdominal and gluteal adipose tissue, that the expressions of some miRNAs are influenced
by cis-located genetic variants and that miRNAs are associated with expression levels of their predicted mRNA targets.
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Introduction
Different adipose depots have distinct endocrine and physio-
logical properties [1,2,3]; increased amounts of abdominal adipose
tissue are associated with an adverse metabolic risk while gluteal
adipose tissue appears to have a relatively protective role with
respect to type 2 diabetes (T2D), hypertension and dyslipidaemia
[4,5]. As the relative distribution of adipose tissue on the human
body is related to the risk for general metabolic deregulation and
increased morbidity, characterisation of the molecular phenotypes
in different adipose depots is an important starting point when
attempting to understand individual molecular mechanisms asso-
ciated with adiposity and related disease risk. Further knowledge of
tissue specific, disease-associated mechanisms may help in deve-
lopment of interventions, as well as preventive measures, to reduce
risk of severe disease.
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mRNA MicroRNAs (miRNAs) are short (19–22 nucleotides), evolution-
arily conserved, non-coding RNA molecules, involved in gene
regulatory functions. MiRNAs operate through a mechanism
involving complementary sequence binding (of a seed region) to
the 39 UTR region of a target mRNA molecule. Formation of the
miRNA:mRNA complex results in either increased degradation of
the target mRNA molecule [6], or alternatively, inhibition of
target mRNA translation [7,8,9]. Through these mechanisms,
miRNAs have been predicted to affect the regulation of up to 30%
of protein coding genes in mammals [8] and are consequently
involved in regulating a broad set of cellular processes [10,11].
Several examples of miRNA-mediated regulation in mammalian
adipose tissue have been reported so far, including miRNA in-
volvement in adipocyte differentiation [12,13] and adipogenesis
[14,15]. Furthermore, the expression levels of several miRNAs
have previously been reported to be associated with obesity,
metabolic syndrome and T2D [16,17,18,19]. The influence of
genetic variants on miRNA expression has recently been reported
in a study of miRNA expression in human fibroblasts [20], where
12 cis miRNA eQTLs were reported as significant, out of the 121
miRNAs tested (N=180), motivating us to assess if genetic drivers
of miRNA expression will also be present in adipose tissue.
Here, we studied global miRNA expression in gluteal and ab-
dominal adipose tissues in 70 human subjects in the MolOBB
study (41 healthy controls and 29 metabolic syndrome cases, see
Materials andMethods), with the objective of characterising the
global miRNA molecular phenotypic profile in these two adipose
depots. To our knowledge, this is the first time a comprehensive
miRNA characterisation has been carried out in human gluteal and
abdominal adipose tissue depots. We have assessed whether mi-
RNAs are differentially expressed between abdominal and gluteal
adipose tissue and to what extent the expression of miRNAs are
associated with metabolic syndrome in each tissue type. To deter-
mine the extent to which miRNA expression in adipose tissue is
associated with predicted mRNA targets, indicating a potential a
gene-regulatory activity of the miRNA, we have also carried out
global mRNA expression profiling in both tissue types in the same
set of subjects. Finally, all subject in the study were SNP genotyped
and miRNA eQTL analysis was carried out, in order to assess
whether miRNA expression levels are genetically driven.
Results
Differential miRNA expression between abdominal and
gluteal adipose tissue
We profiled miRNA expression of 1,146 human miRNAs (based
on miRBase 12.05 and additional in-house predictions by Illumina)
in subcutaneous gluteal and abdominal adipose tissue from 70
human subjects, using the human Illumina miRNA BeadArray
(version 2). A linear mixed-effects model was applied to model the
tissue differential expression for each miRNA while correcting for
relevant covariates, including metabolic syndrome case-control
status (see Materials and Methods). We found 136 (12%)
miRNAs to be significantly differentially expressed (FDR-adjusted
p-value,0.05) between the gluteal and abdominal fat tissue samples
in the primary study (Table S1). Of these, 61 (45%) had higher
expression levels in gluteal fat, while 75 (55%) were expressed at
higher levels in abdominal fat, indicating a clear difference in the
molecular miRNA phenotype in each adipose depot. We also noted
that the expression of 19 (14%) of these depot-specific miRNAs
(Table S1) have previously been reported to be associated with
adipose tissue development, obesity, T2D and metabolic distur-
bances [12,13,15,21,22,23,24,25,26,27,28,29,30,31,32]. Of these,
nine miRNAs (hsa-miR-326 [21], hsa-miR-211 [22,23], hsa-miR-10b
[32], hsa-miR-365 [32], hsa-miR-10a [32], hsa-miR-503 [32], hsa-miR-
335* [30], hsa-miR-331-3p [30] and has-miR-199a-5p [30]) were
expressed at higher levels in abdominal, rather than gluteal, adipose
tissue (Table S1). To confirm that miRNAs with tissue-differential
expression did not have substantial metabolic syndrome case- or
control group specific variability, the analysis was also carried out
separately in each one of the case- and control groups and com-
pared to the joint analysis. Results indicate a high degree of con-
cordancebetween the jointanalysisandanalysisincase-and control
groups separately (correlations of 0.93 and 0.98 were observed be-
tween the effect size estimates in the joint analysis and the separate
analyses in case- and control groups respectively (Figure S1)).
To replicate our results, we repeated the experiment and analysis
in gluteal and abdominal adipose tissue from 40 additional human
subjects (28 healthy controls and 12 metabolic syndrome cases), not
part of the original study (see Materials and Methods), and only
considered miRNAs that werefound to be significant in the primary
study. Of the 136 miRNAs found to be significantly differentially
expressed in the primary study, 59 (44%) were also significantly
differentially expressed in the replication study (p-value,0.05 and
directionally consistent effect) (Figure 1, see Table S1 for detailed
results). When we compared the effect sizes across both the primary
and replication studies, we observed a high degree of overall
concordance (Pearson correlation coefficient=0.86) between the
coefficients (Figure S2), indicating a high level of agreement
between the two studies, even among miRNAs that didnotmeet the
p-value criterion for achieving replication. Seven of the miRNAs
that were differentially expressed in both studies, have previously
beenreportedtoplayaroleintissuedevelopment,obesity,T2Dand
metabolic disturbances (hsa-miR-34a [23,32], hsa-miR-28-5p [32],
hsa-miR-27b [13,15], hsa-miR-326 [21], hsa-miR-204 [22,23], hsa-
miR-195 [32], hsa-miR-519d [29]).
miRNA expression associated with metabolic syndrome
To investigate the extent to which miRNA expression levels are
associated with metabolic syndrome case-control status among the
subjects in this study, we applied a similar model (see Materials
and Methods) to that used in the analysis of tissue differential
expression. The case-control analysis was performed separately
for abdominal and gluteal adipose tissues. In abdominal tissue
we found that 14 miRNAs were associated (FDR adjusted p-
value,0.05) with metabolic syndrome case-control status (primary
study). In the replication study three (21%) out of these 14 mi-
RNAs were replicated (p-value,0.05 and directionally consistent
effect), which is more than expected under the null, at the 0.05
level (p-value=0.03 (one-sided binomial test)). The three replicat-
ed miRNAs, hsa-miR-652, hsa-miR-1179, hsa-miR-7-2*, all had
lower expression levels in the case group. Furthermore, 13 out of
14 miRNAs also had coefficients that were directionally consistent
across the primary and replication studies (Figure S3, Table S2).
In gluteal adipose tissue, 14 miRNAs were differentially expressed
(FDR adjusted p-value,0.05) between case and control groups in
the primary study, but none of these replicated in the replication
study. We did, however, observe directionally consistent effect
estimates for 10 of the 14 miRNAs found to be differentially ex-
pressed in the primary study (Figure S4, Table S3). We note that
the replication study had a lower proportion of metabolic
syndrome cases due to sample availability (30% in comparison
to 41% in the primary study).
miRNA expression-Quantitative Trait Loci (eQTL) analysis
We then carried out miRNA eQTL analysis on the full set of
miRNAs that were profiled, to assess whether genetic variation
influences the expression level of miRNAs. We performed the
MicroRNA Expression in Human Adipose Tissue
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each of the target miRNAs, using a linear mixed-effects model,
assuming an additive genetic effect and correcting for relevant
covariates (see Materials and Methods). Abdominal and
gluteal adipose tissue samples were considered separately in the
miRNA eQTL analysis. We considered cis-SNPs located within an
arbitrarily chosen region of 50 kilobases (kb) up-/down-stream
from the miRNA sequence in the analysis. As in the analysis of
tissue-specific differential miRNA expression (described above), we
employed a likelihood ratio test to establish the ranking and
significance of the genetic effect in each eQTL model (see
Materials and Methods). These analyses revealed a modest
excess of low p-values compared to the null distribution (see
Figure S5). We carried forward 19 miRNA eQTLs in abdominal
fat tissue (Table S4) and 11 in gluteal fat tissue (Table S5) for
replication, using an arbitrary p-value threshold,0.001 (see
Materials and Methods).
The candidate miRNA eQTLs were followed up in the
replication cohort of 40 subjects, where three independent miRNA
eQTL signals were replicated (p-value,0.05 and directionally
consistent effect) in both abdominal adipose tissue (Figure 2A–C,
Figure 3, Table 1) and gluteal adipose tissue (Figure 2D–F,
Figure 4, Table 2). We note that hsa-miR-1255a has a significant
eQTL signal in both abdominal and gluteal adipose tissues
(Table 1 and 2) and was not found to be differentially expressed
between the depots (Table S1).
To investigate whether any of the five miRNA eQTL SNPs
were directly associated with obesity phenotypes (body mass index
and waist hip ratio corrected for BMI), we looked up association p-
values in a genome-wide association study with 113,636 subjects
from the GIANT consortium) [33,34]. We found that none of the
individual miRNA eQTL-related SNPs had a significant (p-
value,0.05) association with either of the two obesity phenotypes
(Table S6), providing no direct evidence that the miRNA eQTL
SNPs are associated with either of these particular phenotypes.
Association between miRNA and target mRNA
expression
An anti-correlated association between the expression level of a
miRNA and its predicted mRNA targets may indicate a potential
mRNA degrading effect of the miRNA [35]. To investigate
whether miRNAs were associated with their mRNA targets in
adipose tissue, we applied a gene set enrichment (GSE) test [36].
Global mRNA expression was profiled using the Affymetrix
human GeneChip HGU133 Plus 2.0 array (see Materials and
Methods) and mRNA expression profiles from 50 of the
abdominal adipose samples and 55 of the gluteal adipose samples
were available for integrated miRNA-mRNA analysis.
For each miRNA with conserved predicted mRNA targets
(defined by TargetScan [37]), a one-sided GSE test was carried out
to test if the miRNA had a significant anti-correlated association
with its set of predicted mRNA targets. The GSE test was based on
statistics from association tests between a particular miRNA and
all of the mRNAs, one at a time, using a linear fixed-effects model
adjusted for relevant covariates, with the miRNA as the predictor
and one mRNA as the response (see Materials and Methods).
Figure 1. Tissue differential expression (the tissue-related fixed-effects coefficients (b)), of the 59 miRNA that were replicated
(p-value,0.05) in the replication study. The coefficients (b) are sorted on effect-size, a positive value indicating higher expression in gluteal
adipose tissue relative abdominal adipose tissue. Error-bars show the standard-error of b for each miRNA.
doi:10.1371/journal.pone.0027338.g001
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highly ranked test statistics within the set of predicted mRNA
targets of the miRNA being tested, with the null hypothesis that
the predicted target set was randomly chosen (see Materials and
Methods). The analysis included 248 profiled miRNAs with
conserved predicted mRNA targets, since these are thought to be
more likely to have a gene-regulatory function [38]. Thus, we
performed 248 GSE analyses. In abdominal adipose tissue 55 out
of 248 (22%) miRNAs were found to have a significant (FDR
adjusted p-value,0.05) association with their predicted conserved
target mRNAs (Table S7). In gluteal adipose tissue, the same
analyses revealed that 23 out of 248 (9%) of miRNAs had a
significant association with their predicted conserved target
mRNAs (Table S8). Eight of the miRNAs that showed significant
associations with their target mRNAs, were common between the
two tissue types: hsa-miR-181a, hsa-miR-186, hsa-miR-30a, hsa-miR-
141, hsa-miR-30d, hsa-miR-590-3p, hsa-miR-128 and hsa-miR-340
(Figure 5A).
Functional analyses based on miRNA-associated mRNAs
in abdominal and gluteal adipose tissue
To determine the general functional characteristics of the
miRNA-related activity in each adipose tissue type, we looked at
miRNAsthatweresignificantlyassociated with theirmRNA targets,
and tested whether or not there was an enrichment of specific
KEGG [39] terms in each tissue. The analyses included the 248
miRNAs with predicted conserved mRNA targets based on Target
Scan, using the same set of miRNAs included in the miRNA-
mRNA GSE analysis (see previous section). For each miRNA that
had a significant association with its set of mRNA targets (based on
the gene set enrichment test), the KEGG terms were extracted for
all of its mRNA targets. KEGG terms were aggregated across the
significant miRNA-mRNA sets separately for each tissue. We then
applied Fisher’s exact test to assess if any of the KEGG terms were
enriched in these candidate sets of KEGG terms (see Materials
and Methods). The analysis revealed an enrichment of 43 KEGG
terms in abdominal adipose tissue (Table S9), and 33 in gluteal
adipose tissue (Table S10) (FDR adjusted p-value,0.05). We
found that 32 of the KEGG terms were common between the two
tissues (Figure 5B). Several of these KEGG terms were related to
obesity, adipocyte differentiation and metabolic dysregulation;
including MAPK signaling pathway, Insulin signaling pathway,
Type II diabetes mellitus and Adipocytokine signalling pathway,
suggesting relevant functionality.
Discussion
Adiposity and body fat distribution are both heritable traits,
while the heritability of body fat distribution is distinct from that of
overall adiposity [40,41,42,43]. Body fat distribution is divided
into two general types: android (upper body or ‘apple’ shape) and
gynoid (lower body or ‘pear’ shape), where an android fat
distribution is more commonly associated with adverse metabolic
outcomes [44]. Recent evidence suggests that these differences are
driven by adipocytes at different fat depots, which have unique
physiological functions and metabolism [45,46,47]. As the relative
distribution of adipose tissue on the human body is related to the
risk of general metabolic dysregulation, characterisation of the
molecular phenotypes in the different adipose tissue depots is an
essential step towards uncovering the individual molecular me-
chanisms associated with adiposity and related disease risk.
Figure 2. Locus plots for miRNA eQTLs that replicated. P-values from the primary study are shown in figure (criteria for replication: p-
value,0.001 in the primary study and p-value,0.05 in the replication study with a directionally consistent effect). A) Abdominal adipose tissue hsa-
miR-1255a:rs1822168 (p-value=1.83E-05 in primary study and p-value=9.91E-03 in replication study) B) Abdominal adipose tissue hsa-miR-618:
rs1716543 (p-value=5.34E-04 in primary study and p-value=5.80E-03 in replication study) C) Abdominal adipose tissue hsa-miR-146a*:rs2961920
(p-value=5.87E-04e in primary study and p-value=6.45E-06 in replication study) D) Gluteal adipose tissue hsa-miR-1255a:rs1822168 (p-value=1.56E-
05 in primary study and p-value=1.65E-04 in replication study), E) Gluteal adipose tissue hsa-miR-1307:rs11191666 (p-value=1.27E-04 in primary
study and p-value=3.55E-04 in replication study), F) Gluteal adipose tissue hsa-miR-330-3p:rs7252175 (p-value=3.85E-04 in primary study and p-
value=4.04E-02 in replication study).
doi:10.1371/journal.pone.0027338.g002
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PLoS ONE | www.plosone.org 4 November 2011 | Volume 6 | Issue 11 | e27338Figure 3. Genetic effects in replicated miRNA eQTLs in abdominal adipose tissue (see Materials and Methods section for criteria).
The violin-plot represents the density of miRNA expression relating to the SNP effect for each genotype (variability relating to the other fixed effects
was regressed out); the line represents the fixed-effect coefficient (b) relating to the SNP effect. A) Primary study hsa-miR-1255a:rs1822168 B) Primary
study hsa-miR-618:rs1716543 C) Primary study hsa-miR-146a*:rs2961920 D) Replication study hsa-miR-1255a:rs1822168 E) Replication study hsa-miR-
618:rs1716543. F) Replication study hsa-miR-146a*:rs2961920.
doi:10.1371/journal.pone.0027338.g003
Table 1. Replicating miRNA eQTLs in abdominal adipose tissue.



























hsa-miR-1255a rs1822168 4 102512567 C 0.133 0.029 1.83E-05 0.081 0.161 0.060 9.91E-03
hsa-miR-618 rs1716543 12 79854071 A 0.207 0.057 5.34E-04 0.316 0.345 0.116 5.80E-03
hsa-miR-146a* rs2961920 5 159844084 C 20.073 0.021 5.87E-04 0.326 20.306 0.058 6.45E-06
amiRNA name,
brs identifier for each SNP,
cchromosome number,
dgenomic location of SNP,
eeffect allele,
fcoefficient for the SNP effect in the primary study,
gstandard error for the SNP coefficient in the primary study,
hp-value for the SNP effect in the primary study,
iFDR adjusted p-value for the SNP effect in the primary study,
jcoefficient for the SNP effect in the replication study,
kstandard error for the SNP coefficient in the replication study,
lp-value for the SNP effect in the replication study.
doi:10.1371/journal.pone.0027338.t001
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PLoS ONE | www.plosone.org 5 November 2011 | Volume 6 | Issue 11 | e27338Figure 4. Genetic effects in replicated miRNA eQTLs in gluteal adipose tissue (see Materials and Methods section for criteria). The
violin-plot represents the density of miRNA expression relating to the SNP effect for each genotype (variability relating to other fixed effects was
regressed out); the line represents the fixed-effect coefficient (b) relating to the SNP effect. A) Primary study hsa-miR-1255a:rs1822168 B) Primary
study hsa-miR-1307:rs11191666. C) Primary study hsa-miR-330-3p:rs7252175 D) Replication study hsa-miR-1255a:rs1822168. E) Follow up study hsa-
miR-1307:rs11191666. F) Replication study hsa-miR-330-3p:rs7252175.
doi:10.1371/journal.pone.0027338.g004
Table 2. Replicating miRNA eQTLs in gluteal adipose tissue.



























hsa-miR-1255a rs1822168 4 102512567 C 0.138 0.029 1.56E-05 0.069 0.169 0.036 1.65E-04
hsa-miR-1307 rs11191666 10 105117268 G 0.221 0.054 1.27E-04 0.282 0.260 0.065 3.55E-04
hsa-miR-330-3p rs7252175 19 50825096 A 20.198 0.053 3.85E-04 0.595 20.338 0.160 4.04E-02
amiRNA name,
brs identifier for each SNP,
cchromosome number,
dgenomic location of SNP,
eeffect allele,
fcoefficient for the SNP effect in the primary study,
gstandard error for the SNP coefficient in the primary study,
hp-value for the SNP effect in the primary study,
iFDR adjusted p-value for the SNP effect in the primary study,
jcoefficient for the SNP effect in the replication study,
kstandard error for the SNP coefficient in the replication study,
lp-value for the SNP effect in the replication study.
doi:10.1371/journal.pone.0027338.t002
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important in both adipose tissue development and metabolism
[16,17,18,19,48]. In this study we have profiled global miRNA
expression in two body fat depots and investigated whether
miRNAs contribute to the overall molecular phenotype in gluteal
and abdominal adipose deposits. Our analysis detected significant
differential miRNA expression between these two fat depots.
Interestingly, a proportion of the miRNAs found to be significantly
differentially expressed in our study, had previously been reported
to play a role in adiposity, adipocyte development/differentiation
and other metabolic disturbances; further highlighting their
importance (Table S1) [12,13,21,22,23,24,25,26,27,28,29,30,
31,32]. Our analysis also revealed three miRNAs (hsa-miR-652,
hsa-miR-1179, hsa-miR-7-2*) differentially expressed between
control and metabolic syndrome groups in abdominal adipose
tissue. Hsa-miR-652 has only three conserved mRNA targets
included in the Target Scan database: ISL1, ACVR2B and PSKH1.
ISL1 is a transcription factor of the LIM/homeodomain family,
involved in regulating expression of the insulin gene in islet cells
[49] and previously noted to be differentially expressed between
visceral and subcutaneous fat and negatively correlated with BMI
[50]. Taken together, our results, supported by recent publica-
tions, reflect an important role of miRNAs in contributing to the
general molecular phenotypic profile in each one of these two
adipose tissues.
Genetic variants affecting miRNA expression suggest a possible
mechanism through which genetic variants can influence down-
stream molecular- or phenotypic traits, and emphasise the need to
characterise the extent to which miRNA expression levels are as-
sociated with common genetic variants in adipose tissue. For ex-
ample, SNPs may exert an effect on miRNA expression, which may
subsequently affect mRNA expression, and ultimately, phenotypic
traits. MiRNA eQTL analysis allows us to assess the first part of this
mode of action. We found that several miRNAs do indeed have
significant eQTLs, suggesting, at least for a subset of miRNAs, that
there is evidence of genetic variation controlling miRNA expression
levels in human adipose tissue. Our results are in line with recent
datafroma studyofhumanfibroblasts[20],aswellasrodent models
ofT2D,wheretheexpression of ,10%ofmiRNAswerereportedto
be under genetic control [23]. We note that the relatively high FDR
adjusted p-values (up to 0.33 in abdominal adipose tissue, and up to
0.6 in gluteal adipose tissue) (Table 1, Table 2) in the eQTL
analysis in the primary study arein line with eQTL results presented
in[20],where a FDR level of0.5 wasreported.Comparingtheset of
cis miRNA eQTL candidates in the primary study with the 12 cis
miRNA eQTL reported in human fibroblasts [20], shows that in
these two studies the detected miRNA eQTLs were not common.
This may suggest that miRNAs expression is tissue-type specific,
which our results also indicate when comparing miRNA expression
between adipose tissue depots.
Since our miRNA analyses revealed differential miRNA ex-
pression associated with adipose tissue depots, metabolic syndrome
and specific cis-located genetic variants, we were interested in
assessing if miRNA variability had any association with target
mRNA expression levels. Such an association, particularly if anti-
correlated, might indicate an active regulatory role of miRNA on
their target mRNAs, providing an indication of down-stream
effects related to miRNA expression variability. Investigation of
associations between miRNA and their predicted conserved mR-
NA targets revealed that a proportion of miRNAs had a significant
effect on their target mRNAs in both abdominal and gluteal
adipose tissue. Finally, we assessed the functional role of miRNA
activity in adipose tissue by means of an enrichment analysis of
KEGG terms in each tissue type. We found that a number of
KEGG terms were common between the two tissue types, in-
cluding MAPK signaling pathway, Insulin signaling pathway,
Type II diabetes mellitus and Adipocytokine signalling pathway.
We also noted that a proportion of the significant KEGG terms
indicated pathways that are potentially relevant for T2D, obesity
and related metabolic disorders in these adipose tissue depots
(Table S9 and S10).
Few of the miRNAs found significant in at least one of the four
analyses (i.e. association with metabolic syndrome case-control,
with cis-located genetic variants, with predicted target mRNAs or
with tissue type) were found to be common across analyses
(Figure S6). In abdominal tissue, hsa-miR-520c-3p/520f, hsa-
miR-519d and hsa-miR-183 were found to be associated with their
target mRNAs, as well as being tissue differentially expressed. Hsa-
miR-7-2* was found to be significantly associated with case-control
status in abdominal tissue and also tissue-differentially expressed.
In gluteal tissue, hsa-miR-27b, hsa-miR-196b and hsa-miR-28-5p
were found to be both associated with their target mRNAs, as well
as being tissue differentially expressed. We note that few miRNAs
were found to be significant in multiple analyses, although this
might be explained by the fact that the current study has limited
power to detect miRNA associations with metabolic syndrome
case-control status and cis- located genetic variants (eQTLs).
Another potential reason for finding only a few miRNAs that were
significantly associated with mRNAs, is that only a subset (248) of
the miRNAs that were profiled have predicted conserved mRNA
Figure 5. (A) Venn diagram showing the number of common and unique miRNAs with significant association to their target mRNAs
in each adipose tissue type. (B) Venn diagram showing the number of common and unique KEGG terms in each adipose tissue type.
doi:10.1371/journal.pone.0027338.g005
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accuracy and limitations of the target prediction algorithms
currently available. Furthermore, we note that the three significant
miRNA eQTLs detected in each tissue were not found to be
associated with metabolic syndrome case-control status. However,
these miRNAs eQTLs may well be associated with other (obesity-
related) traits not included in the current study, which would be of
interest to investigate in future studies.
Despite limitationsinrespect tosamplesizesandstatisticalpower,
the current results have revealed significant miRNA activity in these
body fat depots. Hence, these results should encourage further
studies with larger sample sizes and increased power, necessary to
detect additional miRNA eQTLs in adipose tissue, as well as for
detecting associations between miRNA eQTLs and relevant obe-
fsity-related phenotypes. The results from the miRNA-mRNA
association analysis are also encouraging and highlight the im-
fportance of performing global profiling of both miRNA and
mRNA expression within the same study, in order to determine the
extent to which these two molecular phenotypes are associated.
Our results indicate that there is a clear difference in the
miRNA molecular phenotypic profile of gluteal and abdominal
adipose tissue and that miRNA expression is at least partly driven
by effects related to common genetic variation. Our results also
suggest an association between miRNA and mRNA expression
levels, indicating that miRNAs may play an active role in gene
regulation in adipose tissue. The exact mechanisms through which
miRNAs act are still elusive and future work would need to include
detailed functional studies (for the miRNAs where this is not
already available), as well as proteomic studies, to find evidence of
the implications of miRNA expression changes on the related
protein abundances in adipose tissue.
Materials and Methods
Ethics statement
The study has received ethical approval from National Health
Service (NHS), National Research Ethics Service, Oxfordshire
REC C (REC reference: 08/H0606/107). Informed consent in
writing was obtained from all participants involved in the study.
Study design and experimental material and methods
Sample and subject information – primary study. Tissue
samples from 70 human subjects (40 male and 30 female)
belonging to either a healthy control group (N=41, 24 male, 17
female) or the metabolic syndrome case group (N=29, 16 male,
13 female) were collected from the Oxford Biobank [51]. Meta-
bolic syndrome status was assigned based upon the International
Diabetes Foundation (IDF) criteria [52]. Control subjects were
selected to be discordant from the metabolic syndrome cases.
Adipose tissue samples from abdominal and gluteal adipose tissues
were collected from all subjects. DNA and total RNA were
extracted from each subject and sample.
Sample and subject information – replication study. To
validate results from the primary study, gluteal and abdominal
adipose tissue samples from 40 additional subjects (20 male, 20
female) were collected from the Oxford Biobank. Among the
females 5 subjects were metabolic syndrome cases (3 IDF), and 15
were controls. Among the males 7 subjects were metabolic syn-
drome cases (3 IDF), and 13 were controls. A logistic regression
model for case-control status, estimated on relevant clinical
phenotypes (body mass index, blood high-density lipoprotein
level, blood triglyceride level, blood fasting glucose level, waist
circumference, diastolic blood pressure, systolic blood pressure) in
the primary data set, was used to predict which of the available
subjects in the Oxford Biobank that were most similar to the cases
and controls in the primary study, with the aim of establishing a
relevant and as similar as possible, replication study. Validation
cohort metabolic syndrome subjects consisted of a set of cases
fulfilling the formal IDF criteria, as well as a set of cases that were
predicted as cases through the logistic regression model. As the
main focus of this study is on tissue related effects, the subjects in
the replication study are to be considered as relatively well mat-
ched to the primary study subjects.
Single Nucleotide Polymorphism (SNP) genotyping –
primary study. DNA was extracted from each subject using
GeneCatcher
TM (Invitrogen Life Technologies, Carlsbad, USA)
using manufacturers protocol before being genotyped on the
Illumina 317 k Beadchip platform (Illumina Inc., San Diego, CA,
USA).
Single Nucleotide Polymorphism (SNP) genotyping –
replication study. Genotyping was performed using the
Sequenom iPLEX
TM assays with the mass spectrometry based
MassARRAY
TM platform for genotype detection (Sequenom, San
Diego, USA), according to manufacturer’s protocol.
miRNA expression profiling – primary study. Total RNA
was extracted from homogenized adipose tissue samples from each
subject using TRI Reagent (Sigma, Gillingham, UK) in accordance
with manufacturer’s procedure. RNA quality was assessed using a
spectrophotometer (NanoDrop, Labtech International, UK) and the
Bioanalyzer 2100 (Agilent, South Queensferry, West Lothian, UK).
MiRNA expression profiling was carried out using the Illumina
miRNA BeadArray platform (version 2), 96 sample universal array
matrix format (MI-102-1196). The Illumina miRNA BeadArray
platform includes probes against 859 known human miRNA
sequences and 287 predicted miRNA sequences. Briefly, 400 ng
of miRNA were used per sample, samples were polyadenylated,
converted to biotinylated cDNA and hybridized to the BeadArray,
and then a universal PCR amplification was performed resulting in
fluorescently labelled product labelled by miRNA specific oligo
(MSO) molecules. Arrays were then scanned using the BeadArray
Reader (Illumina, San Diego, US). Samples were measured in
technical duplicates(witha few intriplicates). Due toasmallnumber
of failed assays, data are available from 69 abdominal adipose
samples (140 arrays including technical duplicates) and 66 gluteal
adipose samples (134 arrays including technical duplicates). In total,
data from 70 subjects and two tissue types, measured on 274 arrays,
were available for further analysis in the primary study.
miRNA expression profiling – replication study. In total,
data were collected from 40 subjects and both abdominal and gluteal
adipose tissue, 13 of the 80 samples were measured in duplicates,
resulting in data from 93 arrays available for further analysis in the
replication study. 500 ng of total RNA from each sample were
labelled and hybridized on Universal-12 Illumina BeadChip (Cat.
No. # 11288011), according to the manufacturer’s recommendations
(Illumina microRNA expression profiling assay for BeadChips).
BeadChips were scanned with the Illumina BeadArray scanner
accordingly and images imported into GenomeStudio version 1.6.0
(illumina) to extract the raw data for further analysis.
mRNA expression profiling. Total RNA was extracted with
TRIreagent (SIGMA-ALDRICH) from fat biopsies. RNA expres-
sion was analyzed on the Affymetrix human GeneChip HGU133
Plus 2.0 array (Affymetrix) covering over 47,000 transcripts ge-
nome-wide. Labelled RNA was hybridized onto Affymetrix arrays,
washed, stained and scanned for fluorescence intensity corres-
ponding to gene expression level.
Data preprocessing
All data analysis was carried out using R version 2.9.0 [53]
unless otherwise stated.
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imported into R using the beadarray package [54]. Data was
background corrected by subtracting the background intensity from
the foreground levels and bead summary data was calculated using
the Illumina method. Data were thereafter quantile normalised
between arrays, log2 transformed and expression intensities were
extracted. Normalisation was done separately for abdominal and
gluteal adipose tissue samples for miRNA eQTL analysis, while in
the case of tissue-differential expression analysis, all data were
normalised together. Probes were excluded from further analysis if
the 75
th percentile of expression level in either tissue was lower than
the 25
th percentile of array control probes, resulting in 1131 (out of
1146) probes included for further analysis. Outliers were detected
using Principal Component Analysis (PCA) and the Hotelling T
2
test on the first 3 PCA score components; outliers were defined as
being outside the 0.99 confidence interval in the score space. One
array was defined as an outlier by PCA, two additional arrays were
consideredasoutliersduetosubstantiallyhigheroverallbackground
and foreground signals than other arrays, in total three arrays were
excluded from further analysis. Technical reproducibility was asse-
ssed by calculating the correlation between duplicate array profiles
with results indicating a high degree of concordance (Figure S7).
mRNA expression data preprocessing. mRNA expression
data was collected on the Affymetrix human GeneChip HGU133
Plus 2.0 array and normalized using the RMA method [55]
without background correction (i.e. quantile normalization follow-
ed by robust probe-set summarization). All expression data (from
all abdominal and gluteal samples) were preprocessed together.
Publicly available custom chip-definition files (CDFs) were
downloaded (version 9) (http://brainarray.mbni.med.umich.edu
/Brainarray/Database/CustomCDF/CDF_download.asp) and
used to group probes into sets, each set corresponding to an
Ensembl-annotated gene, resulting 17,209 such genes represented
in the array data. See Dai et al [56] for a description of how these
CDFs were created, along with a comparison of their properties
with the CDFs produced by Affymetrix.
Single nucleotide polymorphism data preprocessing –
primary study. Samples were genotyped using the Illumina 317 k
Beadchip platform. One sample was removed due to non-European
ancestry. SNPs were excluded if MAF,1% or if genotyping success
rate was ,95% and MAF .5%, and if genotyping success rate was
,99% and MAF ,5%. Hardy-Weinberg equilibrium was calculated
by combining all unrelated and SNPs were removed if HWE p-value
was ,0.0001. In total, 69 samples were successfully genotyped for
302765 SNPs.
Single nucleotide polymorphism data preprocessing –
replication study. Completely failing assays (,25% success
rate) were first removed. Thereafter samples with ,85% success
rate were removed. Hardy-Weinberg equilibrium was calculated,
and SNPs with HWE p-value ,0.001 or success rate ,85% were
excluded from further analysis.
Statistical analysis
miRNA eQTL analysis. eQTL analysis was performed for
miRNAs located on chromosome 1–22. We consider cis-eQTLs in
our analysis, cis-located SNP variants were defined as +/2 50 kilo-
bases from miRNA genomic location. 729 miRNAs have at least
one cis-located SNP, in total 9346 miRNA eQTL models were
evaluated. The eQTLs were modelled using a linear mixed-effects
model: yij=m+b*snpi+tgender(i)+gcaseControl(i)+abatch(i,j)+c*agei+ki+eij.S u b j e c t s
are indexed by i M {1…69}, aliquots are indexed by j M {I,2}. yij is the
miRNA expression level of one of the miRNA probe for subject i and
aliquot j. m is overall mean expression level. b is a fixed effect
representing the genetic effect of the SNP variant, where snpi is a
function mapping individual i to the number of copies of the reference
allele {0, 1, 2}. tgender(i) is a fixed effect corresponding to gender for
subject i, where gender(?) is a function mapping individual i to gender M
{male, female}. gcaseControl(i) is a fixed effect representing case/control
status of subject i, where caseControl(?) is a function mapping individual i
to it’s case/control status for metabolic syndrome M{case, control}, cis
a fixed effect incorporating the effect of age, abatch(i,j) is a fixed effect
included to accommodate an experimental batch effect (96-well plate
format), where the function batch(?) is a function mapping each sample
to a batch (plate) M {1,2,3}. The kI are independently Gaussian
distributed with mean zero and variance s
2
k, for subject i representing
inter individual variability. eij is the residual error term incorporating
technical (aliquot) variability, assumed to be independently Gaussian
distributed with mean zero and variance s
2
e. The model was fitted in
R, using the lme4 package[57] and the lmer() function, using
maximum-likelihood. A likelihood ratio test was applied to assess the
significance of the SNP effect (b), which is the parameter of main
interest in the eQTL analysis. The p-value of the SNP effect in each
eQTL model was calculated using a likelihood ratio (LR) test with the
D=22*log(LR) as the test statistic, which can be approximated by a
Chi-square distribution with one degree of freedom. The p-values were
adjusted for multiple testing by FDR correction [58]. In the replication
study the batch effect was omitted from the model due to change of
Illumina platform from 96-array format to 12-array format with no
apparent batch differences present. For the eQTL analysis results were
considered to be replicating in the replication study if the fixed effect of
interest (b) had a p-value,0.05 and consistent direction of the effect. If
quality control criteria for SNP genotyping of particular SNPs were not
met in the replication study, a proxy - SNP were instead reported with
better genotyping quality.
Tissue-differential expression analysis. Al i n e a rm i x e d -
effects model was fitted and evaluated for differential expression
between miRNA expression in gluteal and abdominal tissues:
yijk=m+btissue(k)+tgender(i)+gcaseControl(i)+abatch(i,j)+c*agei+li+kik+eijk.S u b j e c t s
are indexed by i M {1…70}, aliquots are indexed by j M {1,2} and
tissue type is indexed by k M {1,2}. yijk is the miRNA expression level of
one of the miRNA probes for subject i, aliquot jand tissue k. mis overall
mean expression level. btissue(k) is a fixed effect representing the tissue
effect for adipose tissue type M {abdominal, gluteal}. tgender(i) is a fixed
effect corresponding to gender for subject i, where gender(?) is a function
mapping individual i to it’s gender M {male, female}. gcaseControl(i) is a
fixed effect representing case/control status of subject i, where
caseControl(?) is a function mapping individual i to it’s case/control
status for metabolic syndrome M {case, control}, c is a fixed effect
incorporating the effect of age, abatch(i,j) is a fixed effect included to
accommodate an experimental batch effect (96-well plate format),
where the function batch(?) is a function mapping each sample to a
batch (plate) M {1,2,3}. The li are independently Gaussian distributed
with mean zero and variance s
2
l, for subject i, representing inter-
individual variability across tissues. kik are independently Gaussian
distributed with mean zero and variance s
2
k, for subject i and tissue k,
representing within-individual variability. eijk is the residual error term,
incorporating technical (aliquot) variability, assumed to be inde-
pendently Gaussian distributed with mean zero and variance s
2
e.T h e
model was fitted in R, using the lme4 package[57] and the lmer()
function, using maximum-likelihood. A likelihood ratio test was applied
to assess the significance of the tissue effect (b), which is the parameter
of main interest in the tissue differential expression analysis. The p-
value of the tissue effect in each model was calculated using a likelihood
ratio (LR) test with the D=22*log(LR) as the test statistic, which can
be approximated by a Chi-square distribution with one degree of
freedom. The p-values were adjusted for multiple testing by FDR
correction [58]. In the replication study the batch effect was omitted
from the model due to change of Illumina platform from 96-array
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For the tissue-differential analysis results were considered to be repli-
cating if the fixed effect of interest (b) had a p-value,0.05 and
consistent direction of the effect.
Metabolic syndrome case-control analysis. Metabolic
syndrome case-control analysis was performed using a linear mixed-
effects model: yij=m+tgender(i)+gcaseControl(i)+abatch(i,j)+c*agei+ki+eij.T h e
analysis was performed separately for each tissue. Subjects are
indexed by i M {1…70}, aliquots are indexed by j M {I,2}. yij is the
miRNA expression level of one of the miRNA probe for subject i and
aliquot j. m is overall mean expression level. tgender(i) is a fixed effect
corresponding to gender for subject i, where gender(?) is a function
mapping individual i to it’s gender M {male, female}. gcaseControl(i) is a
fixed effect representing case/control status of subject i, where
caseControl(?) is a function mapping individual i to it’s case/control
status for metabolic syndrome M {case, control}, c is a fixed effect
incorporating the effect of age, abatch(i,j) is a fixed effect included to
accommodate an experimental batch effect (96-well plate format),
where the function batch(?) is a function mapping each sample to a
batch (plate) M {1,2,3}. The ki are independently Gaussian distributed
with mean zero and variance s
2
k, for subject i representing inter
individual variability. eij is the residual error term incorporating
technical (aliquot) variability, assumed to be independently Gaussian
distributed with mean zero and variance s
2
e. The model was fitted
in R, using the lme4 package[57] and the lmer() function, using
maximum-likelihood. A likelihood ratio test was applied to assess the
significance of the case-control effect (g). The p-value of the case-
control effect in each model was calculated using a likelihood ratio (LR)
test with the D=22*log(LR) as the test statistic, which can be
approximated by a Chi-square distribution with one degree of
freedom. The p-values were adjusted for multiple testing by FDR
correction [58]. In the replication study the batch effect was omitted
from the model due to change of Illumina platform from 96-array
format to 12-array format with no apparent batch differences present.
Results were considered to be replicating if the fixed effect of interest (g)
had a p-value,0.05 and consistent direction of the effect.
miRNA-mRNA analysis. The TargetScan database [37] was
used to provide mRNA target predictions for each miRNA in the
miRNA-mRNA analysis, here using predicted and conserved
targets. TargetScan prediction was accessed through the R-
package targetscan.Hs.eg.db (version 0.2.0). 248 of the miRNAs we
have profiled have predicted conserved targets, for each one of
these we assessed if there was an association with their target
mRNAs. We defined an overall association through a statistical
gene set test using the mean-rank gene set enrichment method
(MR-GSE) [36]. We started with modelling the association
between each miRNA and the full set of mRNAs profiled using
a linear fixed-effects model with one mRNA as response variable,
and the miRNA together with gender, age, metabolic syndrome
case/control status, and batch as covariates. The mRNAs were
ranked by their miRNA-associated t-statistic, in this case we were
performing an one-sided test to assess if there were evidence for
anti-correlated enrichment (i.e. negative t-statistic). The null
hypothesis in the MR-GSE test is that the set of predicted target
mRNAs are randomly chosen from the full set (i.e. all mRNAs
profiled), p-values were calculated as for the Wilcoxon two-sample
rank test [36]. The MR-GSE test was applied using functionality
provided by the limma-package for R. P-values were adjusted for
multiple testing by FDR correction [58] across the 248 performed
enrichment tests. The miRNA-mRNA analysis was based upon 50
subjects with both miRNA and mRNA data available in
abdominal adipose tissue and 55 subjects in gluteal adipose tissue.
Functional annotations using KEGG and miRNA-mRNA
associations. The KEGG database [39] was used to provide an
overall functional annotation based on detected miRNA-mRNA
associations in each tissue. MiRNAs found to have a significant
association with their mRNA target set using the above outlined
gene set enrichment test (FDR adjusted p-value,0.05) were
included in this analysis. KEGG terms corresponding to all m-
RNA targets for these miRNAs were aggregated within each tissue
type. To testforsignificant enrichment of individual KEGGterms, a
Fisher exact test was applied, comparing against the overall universe
of KEGG terms in the full set of mRNAs profiled. P-values were
subsequently adjusted for multiple testing by FDR correction [58].
Supporting Information
Figure S1 Comparison of effect size estimates for miRNAs with
tissue differential expression. (A) Effect size estimates from the joint
analyis (both metabolic syndrome case and control subject
included) vs. control subjects only. (B) Effect size estimates from
the joint analyis (both metabolic syndrome case and control
subject included) vs. metabolic syndrome case subjects only.
(TIF)
Figure S2 Reproducibility of estimated tissue differential mi-
RNA expression effects (b). Plot of primary study coefficients vs.
replication study coefficients for all miRNAs that were found to be
significantly differentially expressed in the primary study. The
linear relationship between the coefficients indicate that there is a
relatively high-degree of concordance between the two studies.
Error-bars indicate the standard-error of b for each miRNA.
(TIF)
Figure S3 Reproducibility of estimated metabolic syndrome
associated differential miRNA expression effects in abdominal
adipose tissue. Plot of primary study coefficients vs. replication
study coefficients for all miRNAs that were found to be sig-
nificantly differentially expressed in the primary study. Error-bars
indicate the standard-error of b for each miRNA.
(TIF)
Figure S4 Reproducibility of estimated metabolic syndrome
associated differential miRNA expression effects in gluteal adipose
tissue. Plot of primary study coefficients vs. replication study
coefficients for all miRNAs that were found to be significantly
differentially expressed in the primary study. Error-bars indicate
the standard-error of b for each miRNA.
(TIF)
Figure S5 Distribution of p-values for miRNA eQTL models. B)
Quantile-Quantile plot of p-values in abdominal fat tissue (ge-
nomic control analysis [59] parameter l=1.12) C) Histogram of
p-values in gluteal adipose tissue. D) Quantile-Quantile plot of p-
values in abdominal fat tissue (genomic control analysis [59]
parameter l=1.09).
(TIF)
Figure S6 Comparison of significant miRNAs across analyses. (A)
Common significant miRNAs between tissue differential expression
analysis (tissue) and metabolic syndrome case-control (Case-Con.)
association, target mRNA association (mRNA) and miRNA eQTLs
(eQTL) in abdominal adipose tissue. (B) Common significant miRNAs
between tissue differential expression analysis (tissue) and metabolic
syndrome case-control (Case-Con.) association, target mRNA associ-
ation (mRNA) and miRNA eQTLs (eQTL) in gluteal adipose tissue.
(TIF)
Figure S7 Histogram of correlations between pairs of (technical)
duplicate array profiles in the primary study. Results indicate a high
degree of concordance between technical duplicate measurements.
(TIF)
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